Sensus Healthcare Reports Record Second Quarter Financial Results Revenue growth of 39% marks seventh consecutive quarter of double-digit year-over-year gains Conference call begins at 4:30 Eastern time today BOCA RATON,

Healthcare Reports Record Second Quarter Financial Results

growth of 39% marks seventh consecutive quarter of double-digit year-over-year gains

call begins at 4:30 Eastern time today

RATON, Fla. (August 3, 2017) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the

non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial

results for the three and six months ended June 30, 2017.

of the second quarter of 2017 and recent weeks include (all comparisons are with the second quarter of 2016, unless otherwise

are proud to report another excellent quarter of financial results as we achieved record revenues and marked a seventh consecutive

quarter of double-digit year-over-year growth," said Joe Sardano, chairman and chief executive officer of Sensus Healthcare.

"Our installed base grew to 295 units with 69 of those units treating keloids as well as skin cancer. Half of the 16 SRT

systems we shipped during the quarter were our higher end SRT-100 Vision systems, reflecting the sophistication and dedication

to patient health of our physician customers. In addition, we are starting to see the planned ROI from the expansion of our sales

organization as representatives hired several months ago are becoming productive. We now have 22 direct sales representatives,

compared with 17 at the beginning of the year.

clearly is gaining acceptance in the medical community with a growing roster of customers who are key opinion leaders in their

fields. In addition, these KOLs are speaking out on our behalf at important industry conferences, presenting the benefits of SRT

in treating non-melanoma skin cancers and keloids. Our marketing efforts are also succeeding in drawing attention to the treatment

of keloids, and the SRT-100 has been featured in human interest media stories. We are working hard to bring SRT to the radiation

oncology marketplace as well, and exhibited last weekend at the American Association of Physicists in Medicine Annual Meeting.

are making a great deal of progress in our efforts to expand the use of SRT and our products outside the U.S. The SRT-100 received

clearance by the China Food and Drug Administration for the treatment and prevention of keloids, which is in addition to our previous

clearance in China for non-melanoma skin cancer. We're looking forward to an expected formal launch by our partner Chindex

Medical in October at the International Congress of the Dermatologic & Aesthetic Surgery International League (DASIL) in Shanghai.

We have submitted the paperwork for regulatory clearance in Mexico, and hope to receive approval to sell the SRT-100 there in

Sardano added, "As anticipated, our financial results reflect an increase in research and development expenses this year

to accelerate sales into new indications and provide new product features during 2018. We have several sites poised to begin studies

with the SRT-100 Vision for the treatment of psoriasis, and we are right on schedule in our development work for the use of SRT

in intraoperative radiation therapy for breast and other cancers. In addition, our development work with our next-generation SRT

product is proceeding as planned."

Results for the Three Months Ended June 30, 2017

for the second quarter of 2017 increased 39% to $5.0 million, compared with $3.6 million for the second quarter of 2016. The increase

was primarily the result of a strong contribution from the SRT-100 Vision, which has a higher average selling price, and to an

increase in overall units sold.

profit for the second quarter of 2017 was $3.4 million, or 68.7% of revenue, compared with $2.3 million, or 65.0% of revenue,

for the second quarter of 2016. Both gross profit and gross margin were positively affected by the increase in sales of SRT-100

and marketing expenses were $2.1 million for the second quarter of 2017, compared with $1.2 million for the second quarter of

2016, reflecting increased sales team headcount as well as higher advertising, trade show and other marketing expenses.

and administrative expenses for the second quarter of 2017 were $0.9 million, compared with $1.1 million for the second quarter

of 2016. The decrease was primarily due to lower stock compensation expense and professional fees, offset by higher director and

officer insurance premiums and other public company expenses following the company's initial public offering in June 2016.

and development expenses for the second quarter of 2017 were $1.2 million, compared with $0.4 million for the second quarter of

2016, primarily due to the continued investment in the next-generation SRT and projects for additional SRT indications that began

in the fourth quarter of 2016.

net loss for the second quarter of 2017 was $0.8 million, or $0.06 per share, compared with a net loss of $0.4 million, or $0.03

per share, for the second quarter of 2016.

EBITDA for the second quarter of 2017 was a negative $0.6 million, compared with a positive $0.2 million for the second quarter

of 2016. Adjusted EBITDA is defined as earnings before depreciation and amortization, income taxes, interest expense and stock

compensation expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the specific reasons

these non-GAAP financial measures are provided.

cash equivalents and investments were $10.6 million as of June 30, 2017. The Company has no long-term debt.

Results for the Six Months Ended June 30, 2017

for the six months ended June 30, 2017 increased 41% to $9.3 million, compared with $6.6 million for six months ended June 30,

2016. Gross profit for the six months ended June 30, 2017 was $6.3 million, or 67.2% of revenue, compared with $4.3 million, or

64.4% of revenue, for the six months ended June 30, 2016. Selling and marketing expenses were $4.4 million for six months ended

June 30, 2017, compared with $2.1 million for the six months ended June 30, 2016. General and administrative expenses were $2.0

million for six months ended June 30, 2017, compared with $1.8 million for the six months ended June 30, 2016. Research and development

expenses for the six months ended June 30, 2017 were $2.3 million, compared with $0.7 million for the six months ended June 30,

2016. The net loss for the six months ended June 30, 2017 was $2.3 million, or $0.18 per share, compared with a net loss of $0.3

million, or $0.03 per share, for the six months ended June 30, 2016.

of Non-GAAP Financial Information

press release contains supplemental financial information determined by methods other than in accordance with accounting principles

generally accepted in the United States of America ("GAAP"). Sensus Healthcare's management uses Adjusted EBITDA,

a non-GAAP financial measure, in its analysis of performance. Adjusted EBITDA should not be considered a substitute for GAAP basis

measures nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Management believes

the presentation of Adjusted EBITDA, which excludes the impact of interest expense, income taxes, depreciation, amortization and

stock compensation expense, provides useful supplemental information that is essential to a proper understanding of the financial

results of Sensus Healthcare. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation

methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that

Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude

items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA

is provided in the schedule below.

TO NON-GAAP RECONCILIATION

Company will host an investment community conference call today at 4:30 p.m. Eastern time, during which management will discuss

financial results for the second quarter of 2017, provide a business update and answer questions. To access the conference call,

the dial-in numbers are 877-870-4263 (U.S. Toll Free), 412-317-0790 (International) and 855-669-9657 (Canada Toll Free). Please

direct the operator to be connected to the Sensus Healthcare call.

the conclusion of the conference call, a replay will be available through August 10, 2017 and can be accessed by dialing 877-344-7529

(U.S. Toll Free), 412-317-0088 (International) or 855-669-9658 (Canada Toll Free). All listeners should provide the replay passcode

10110870. The call will also be archived on the Company website for a time at http://www.sensushealthcare.com.

press release includes statements that are, or may be deemed, forward-looking statements.'' In some

cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes,"

"estimates," "anticipates," "expects," "plans," "intends," "may,"

"could," "might," "will," "should," "approximately," "potential"

or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements

contain these words.

their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics,

and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the

future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each

forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of

future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry

in which we operate may differ materially from the forward looking statements contained in this press release, as a result of,

among other factors: our ability to achieve and sustain profitability; market acceptance of the SRT-100 product line; our ability

to successfully commercialize our products, including the SRT-100; our ability to compete effectively in selling our products

and services, including responding to technological change and cost containment efforts of our customers; our need and ability

to obtain additional financing in the future, as well as complying with the restrictions our existing revolving credit facility

imposes; our ability to expand, manage and maintain our direct sales and marketing organizations; our actual financial results

may vary significantly from forecasts and from period to period; our ability to successfully develop new products, improve or

enhance existing products or acquire complementary products, technologies, services or businesses; our ability to obtain and maintain

intellectual property of sufficient scope to adequately protect our products, including the SRT-100, and our ability to avoid